Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea · Delayed Price · Currency is KRW 1,617,000
-40,000 (-2.41%)
Last updated: Mar 12, 2026, 1:25 PM KST
Samsung Biologics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 4,556,972 | 3,497,146 | 3,694,589 | 3,001,295 | 1,568,007 |
Other Revenue | -0 | -0 | - | -0 | - |
| 4,556,972 | 3,497,146 | 3,694,589 | 3,001,295 | 1,568,007 | |
Revenue Growth (YoY) | 30.30% | -5.34% | 23.10% | 91.41% | 34.62% |
Cost of Revenue | 2,056,131 | 1,798,093 | 1,900,080 | 1,540,526 | 844,657 |
Gross Profit | 2,500,841 | 1,699,053 | 1,794,509 | 1,460,769 | 723,350 |
Selling, General & Admin | 357,259 | 313,046 | 535,421 | 380,456 | 169,630 |
Research & Development | 37,181 | 36,711 | 81,588 | 45,884 | 954.22 |
Amortization of Goodwill & Intangibles | 13,797 | 10,948 | 9,977 | 7,700 | 4,572 |
Other Operating Expenses | 5,970 | 4,688 | 10,339 | 7,448 | 1,804 |
Operating Expenses | 431,620 | 377,686 | 680,829 | 477,142 | 186,040 |
Operating Income | 2,069,221 | 1,321,366 | 1,113,680 | 983,627 | 537,309 |
Interest Expense | -29,171 | -34,123 | -81,596 | -64,064 | -14,707 |
Interest & Investment Income | 46,034 | 54,404 | 95,650 | 53,293 | 9,656 |
Earnings From Equity Investments | 43,085 | 2,659 | -499.42 | 27,260 | 13,853 |
Currency Exchange Gain (Loss) | -7,447 | 41,832 | -11,186 | -63,503 | 17,874 |
Other Non Operating Income (Expenses) | 2,352 | 1,361 | 2,652 | 2,347 | 4,494 |
EBT Excluding Unusual Items | 2,124,074 | 1,387,500 | 1,118,701 | 938,960 | 568,479 |
Gain (Loss) on Sale of Investments | - | - | 5,152 | 72,653 | 269.12 |
Gain (Loss) on Sale of Assets | -5,443 | -1,949 | -3,866 | -2,588 | -7,466 |
Asset Writedown | - | -682.1 | - | - | - |
Pretax Income | 2,118,631 | 1,384,869 | 1,119,987 | 1,009,025 | 561,283 |
Income Tax Expense | 504,301 | 344,567 | 262,296 | 210,968 | 167,693 |
Earnings From Continuing Operations | 1,614,330 | 1,040,302 | 857,691 | 798,056 | 393,589 |
Earnings From Discontinued Operations | 170,022 | 43,014 | - | - | - |
Net Income to Company | 1,784,352 | 1,083,316 | 857,691 | 798,056 | 393,589 |
Net Income | 1,784,352 | 1,083,316 | 857,691 | 798,056 | 393,589 |
Net Income to Common | 1,784,352 | 1,083,316 | 857,691 | 798,056 | 393,589 |
Net Income Growth | 64.71% | 26.31% | 7.47% | 102.76% | 63.33% |
Shares Outstanding (Basic) | 67 | 71 | 46 | 45 | 43 |
Shares Outstanding (Diluted) | 67 | 71 | 46 | 45 | 43 |
Shares Change (YoY) | -5.85% | 53.75% | 1.95% | 5.51% | - |
EPS (Basic) | 26628.00 | 15221.00 | 18528.27 | 17592.79 | 9146.19 |
EPS (Diluted) | 26628.00 | 15221.00 | 18528.27 | 17577.11 | 9146.19 |
EPS Growth | 74.94% | -17.85% | 5.41% | 92.18% | 63.33% |
Free Cash Flow | 856,067 | 355,682 | 671,158 | -3,792 | 48,343 |
Free Cash Flow Per Share | 12775.14 | 4997.47 | 14498.68 | -83.52 | 1123.38 |
Gross Margin | 54.88% | 48.58% | 48.57% | 48.67% | 46.13% |
Operating Margin | 45.41% | 37.78% | 30.14% | 32.77% | 34.27% |
Profit Margin | 39.16% | 30.98% | 23.21% | 26.59% | 25.10% |
Free Cash Flow Margin | 18.79% | 10.17% | 18.17% | -0.13% | 3.08% |
EBITDA | 2,702,858 | 1,920,468 | 1,603,462 | 1,291,892 | 699,098 |
EBITDA Margin | 59.31% | 54.92% | 43.40% | 43.04% | 44.59% |
D&A For EBITDA | 633,637 | 599,101 | 489,782 | 308,264 | 161,789 |
EBIT | 2,069,221 | 1,321,366 | 1,113,680 | 983,627 | 537,309 |
EBIT Margin | 45.41% | 37.78% | 30.14% | 32.77% | 34.27% |
Effective Tax Rate | 23.80% | 24.88% | 23.42% | 20.91% | 29.88% |
Advertising Expenses | 6,615 | 7,180 | 11,916 | 8,829 | 5,349 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.